NO20022525L - Farmasöytiske formuleringer inneholdende zolmitriptan - Google Patents

Farmasöytiske formuleringer inneholdende zolmitriptan

Info

Publication number
NO20022525L
NO20022525L NO20022525A NO20022525A NO20022525L NO 20022525 L NO20022525 L NO 20022525L NO 20022525 A NO20022525 A NO 20022525A NO 20022525 A NO20022525 A NO 20022525A NO 20022525 L NO20022525 L NO 20022525L
Authority
NO
Norway
Prior art keywords
pharmaceutical formulations
formulations containing
zolmitriptan
containing zolmitriptan
formulation
Prior art date
Application number
NO20022525A
Other languages
English (en)
Other versions
NO20022525D0 (no
NO322119B1 (no
Inventor
Alan Roy Dearn
Sarah Louise Williamson
Simon John Summers
Trevor John Coomber
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20022525(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20022525D0 publication Critical patent/NO20022525D0/no
Publication of NO20022525L publication Critical patent/NO20022525L/no
Publication of NO322119B1 publication Critical patent/NO322119B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20022525A 1999-12-03 2002-05-28 Farmasøytiske formuleringer inneholdende zolmitriptan for intranasal administrering NO322119B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9928578.5A GB9928578D0 (en) 1999-12-03 1999-12-03 Pharmaceutical formulations
PCT/GB2000/004528 WO2001039772A1 (en) 1999-12-03 2000-11-28 Pharmaceutical formulations containing zolmitriptan

Publications (3)

Publication Number Publication Date
NO20022525D0 NO20022525D0 (no) 2002-05-28
NO20022525L true NO20022525L (no) 2002-05-28
NO322119B1 NO322119B1 (no) 2006-08-14

Family

ID=10865629

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022525A NO322119B1 (no) 1999-12-03 2002-05-28 Farmasøytiske formuleringer inneholdende zolmitriptan for intranasal administrering

Country Status (28)

Country Link
US (2) US6750237B1 (no)
EP (1) EP1237551B1 (no)
JP (1) JP2003515559A (no)
KR (1) KR100670092B1 (no)
CN (1) CN1222287C (no)
AT (1) ATE291914T1 (no)
AU (1) AU778092B2 (no)
BR (1) BRPI0016138B8 (no)
CA (1) CA2392050C (no)
CZ (1) CZ301528B6 (no)
DE (1) DE60019162T2 (no)
EE (1) EE05305B1 (no)
ES (1) ES2236001T3 (no)
GB (2) GB9928578D0 (no)
HK (2) HK1048445B (no)
HU (1) HU229458B1 (no)
IL (2) IL149578A0 (no)
IS (1) IS2135B (no)
MX (1) MXPA02005319A (no)
NO (1) NO322119B1 (no)
NZ (1) NZ518862A (no)
PL (1) PL200679B1 (no)
PT (1) PT1237551E (no)
RU (1) RU2255736C2 (no)
SK (1) SK287228B6 (no)
UA (1) UA75059C2 (no)
WO (1) WO2001039772A1 (no)
ZA (1) ZA200203704B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
US20050256182A1 (en) * 2004-05-11 2005-11-17 Sutter Diane E Formulations of anti-pain agents and methods of using the same
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
JP2008500288A (ja) * 2004-05-28 2008-01-10 イメイジノット ピーティーワイ エルティーディー 経口治療用化合物の供給系
EP1812428A2 (en) * 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
CN100341504C (zh) * 2004-12-01 2007-10-10 鲁南制药集团股份有限公司 佐米曲普坦速释制剂
EP3263117A1 (en) * 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
JP2010507585A (ja) * 2006-10-19 2010-03-11 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換インドール
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
MX353625B (es) 2010-10-15 2018-01-22 Contera Pharma Aps Combinaciones de agonistas del receptor de serotonina para el tratamiento de trastornos de movimiento.
JP6121734B2 (ja) * 2012-02-09 2017-04-26 久光製薬株式会社 マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス
HUE037732T2 (hu) 2012-04-18 2018-09-28 Contera Pharma Aps A mozgászavarok fejlett kezelésére alkalmas, szájon át szedhetõ gyógyszerészeti készítmény
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
KR101624049B1 (ko) 2014-10-29 2016-05-24 연세대학교 산학협력단 사카린을 이용한 용해도를 증가시킨 약제학적 조성물
EP3310360B1 (en) * 2015-06-19 2024-03-27 Beijing Artivila BioPharma Co. Ltd. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
KR102443161B1 (ko) 2016-07-11 2022-09-14 콘테라 파르마 에이/에스 아침 운동 불능을 치료하기 위한 박동성 약물 전달 시스템
WO2019126766A1 (en) * 2017-12-21 2019-06-27 Taiwan Liposome Co., Ltd. Sustained-release triptan compositions and method of use the same through subdermal route or the like
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69132691T2 (de) * 1990-06-07 2002-06-20 Astrazeneca Ab, Soedertaelje Indolderivate als 5-HT1-like Agonisten
GB9012672D0 (en) * 1990-06-07 1990-08-01 Wellcome Found Therapeutic heterocyclic compounds
GB9516145D0 (en) * 1995-08-07 1995-10-04 Wellcome Found Improved chemical synthesis
EP1024833A1 (en) * 1996-07-11 2000-08-09 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
GB2315673A (en) 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
WO1998034595A1 (de) 1997-02-05 1998-08-13 Jago Research Ag Medizinische aerosolformulierungen
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
IL149578A (en) 2008-04-13
EE05305B1 (et) 2010-06-15
DE60019162T2 (de) 2006-02-02
GB2373726B (en) 2004-10-20
ZA200203704B (en) 2003-10-29
NZ518862A (en) 2004-02-27
KR20020058051A (ko) 2002-07-12
MXPA02005319A (es) 2002-12-06
US7220767B2 (en) 2007-05-22
GB9928578D0 (en) 2000-02-02
US6750237B1 (en) 2004-06-15
PL200679B1 (pl) 2009-01-30
GB0214845D0 (en) 2002-08-07
IL149578A0 (en) 2002-11-10
IS6394A (is) 2002-05-24
BRPI0016138B8 (pt) 2021-05-25
ES2236001T3 (es) 2005-07-16
EE200200283A (et) 2003-06-16
UA75059C2 (uk) 2006-03-15
SK287228B6 (sk) 2010-03-08
CZ20021901A3 (cs) 2002-11-13
US20040214899A1 (en) 2004-10-28
AU778092B2 (en) 2004-11-18
IS2135B (is) 2006-08-15
RU2255736C2 (ru) 2005-07-10
HK1048445B (en) 2005-08-26
CA2392050A1 (en) 2001-06-07
EP1237551A1 (en) 2002-09-11
BR0016138A (pt) 2002-08-06
HU229458B1 (en) 2013-12-30
DE60019162D1 (de) 2005-05-04
HK1048445A1 (en) 2003-04-04
HK1048442B (zh) 2005-05-13
NO20022525D0 (no) 2002-05-28
HK1048442A1 (en) 2003-04-04
PL357597A1 (en) 2004-07-26
AU1715701A (en) 2001-06-12
WO2001039772A1 (en) 2001-06-07
HUP0203597A2 (hu) 2003-02-28
HUP0203597A3 (en) 2005-07-28
EP1237551B1 (en) 2005-03-30
CZ301528B6 (cs) 2010-04-07
CA2392050C (en) 2009-11-24
RU2002117649A (ru) 2004-01-27
NO322119B1 (no) 2006-08-14
CN1222287C (zh) 2005-10-12
HK1053430A1 (en) 2003-10-24
CN1402636A (zh) 2003-03-12
JP2003515559A (ja) 2003-05-07
ATE291914T1 (de) 2005-04-15
BR0016138B1 (pt) 2013-09-10
KR100670092B1 (ko) 2007-01-17
PT1237551E (pt) 2005-07-29
SK7532002A3 (en) 2002-12-03
GB2373726A (en) 2002-10-02

Similar Documents

Publication Publication Date Title
NO20022525D0 (no) Farmasöytiske formuleringer inneholdende zolmitriptan
GB0005251D0 (en) Therapeutic compounds
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
ID27504A (id) Formulasi oral baru
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
DK0907365T3 (da) Hidtil ukendt formulering
SE9802208D0 (sv) Novel compounds
NO20004419D0 (no) Ny anvendelse
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DK1112060T3 (da) Doseringsform anvendende flydende formulering
ATE301999T1 (de) Racecadotril enthaltende trockene pulverformulierung
YU16399A (sh) ) UPOTREBA INHIBITOR H +, K+ - ATP- aze I FARMACEUTSKA FORMULACIJA ZA SIMULTANU, SEPARATNU ILI SEKVENCIJALNU UPOTREBU, KOJA SADRZI INHIBITOR H +, K+-ATP- aze I GLUKOKORTIKOID INHIBITOR H +, K+- ATP- aze
SE0001916D0 (sv) Novel formulation
SE9802209D0 (sv) Novel compounds
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
ES2159479A1 (es) Nuevos indazoles como inhibidores de la ciclooxigenasa-ii
TR200000916T2 (tr) İkameli piperidin türevleri.
ATE247976T1 (de) 10-formyltetrahydrofolate dehydrogenase als therapeutischen mittel

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GRUENENTHAL GMBH, DE

MK1K Patent expired